Summit Therapeutics (SUMM)
SUMM Share PerformanceMore
|52 week high||262.00 04/10/16|
|52 week low||82.75 04/03/16|
|52 week change||79.50 (71.95%)|
|4 week volume||622,843 28/01/17|
Media for (SUMM)
Presenter: Mark Wilcox
Presenter: Mark Wilcox
- 1 of 2
Latest News« previous» nextMore
23/02/2017 - 12:15 RNS
Summit Therapeutics plc: Exercise of Warrants Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF WARRANTS Oxford, UK, 23 February 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...
02/02/2017 - 14:10 StockMarketWire
Summit Therapeutics has announced that company management will participate in three upcoming investor conferences ...
02/02/2017 - 12:00 RNS
Summit Therapeutics to Participate in February Investor Conferences Summit Therapeutics plc ("Summit", the "Company", or the "Group") SUMMIT THERAPEUTICS TO PARTICIPATE IN FEBRUARY INVESTOR CONFERENCES Oxford, UK, 2 February 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development c...
01/02/2017 - 13:36 StockMarketWire
Summit Therapeutics has outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory ...
01/02/2017 - 12:00 RNS
Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT OUTLINES PHASE 3 PROGRAMME FOR NOVEL CDI ANTIBIOTIC RIDINILAZOLE FOLLOWING FDA AND EMA REGULATORY MEETINGS Oxford, UK, 1 February 2017 - Summit Therapeutics plc (AIM...
25/01/2017 - 12:45 RNS
Summit Therapeutics plc: Holding(s) in Company TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii SUMMIT THERAPEUTICS PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An...
19/01/2017 - 16:11 RNS
Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit", the "Company" or the "Group") EXERCISE OF SHARE OPTIONS Oxford, UK, 19 January 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infec...
18/01/2017 - 12:00 RNS
Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development Summit Therapeutics plc ('Summit', 'Company' or the 'Group') SUMMIT APPOINTS DR DAVID ROBLIN AS CHIEF OPERATING OFFICER AND PRESIDENT OF RESEARCH & DEVELOPMENT Oxford, UK, 18 January 2017 - Summit Therapeutics plc (A...
|Dividend yield||0 %|
Latest discussion posts More
“Good RNS today to push sp up around 13% to #1.90. The FDA and EMA have agreed with Summit the parameters for the Phase 3 trials. Essentially the authorities want the Phase 3 ...”▼
“Great to see sp recovering from the 140s pre new year. Expect to see C dif deal before end of H1. Progress on DMD scientific or anecdotal could come at any time by end of H1. ...”▼
“At this rate SUMM sp will end 2017 lower than it started. AFAIK the drivers for 2017 will be the C-Dif Riddy drug comparison study as against Fidoximicin and that should be Q1 ...”▼
Codes & Symbols
|Symbols||SUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM|